Jefferies Healthcare Conference. John Bishop Chairman & CEO June 2, 2014
|
|
- Ilene Ward
- 6 years ago
- Views:
Transcription
1 Jefferies Healthcare Conference John Bishop Chairman & CEO June 2, Cepheid Cepheid
2 Worldwide Market Growth by Segment Overall IVD sales are projected to grow at a 5.9% CAGR through Molecular Diagnostics will remain the highest growth segment. Total = $68.6 B Segment CAGR % Flow Cytometry Immunohematology Histology/Cytology Microbiology Molecular Diagnostics Hem/Coag Clinical Chemistry Immunoassay Point of Care Total = $51.9 B +5.9% CAGR Point of Care (Whole Blood Glucose) 2.3% Point of Care (All other) 8.1% Immunoassays 5.9% Clinical Chemistry 3.4% Hematology/Coagulation 3.0% Molecular Diagnostics 11.9% Microbiology 5.0% Histology/Cytology 9.3% Immunohematology 4.4% Flow Cytometry 6.9% Total Market 5.9% 2 Market Diagnostics 2 International
3 Worldwide MDx Market Overview Two-thirds of 2012 Molecular Diagnostics market revenue was from diagnostic virology and bacteriology. Discipline 2012 ($ Billion) Percent of Total Total Market: $4.6 Billion Virology $1.7 37% Bacteriology $1.2 26% Genetics/Genomics $0.9 20% Blood Screening $0.8 17% Total Market $ % 3 Market Diagnostics 3 International
4 US MDx Laboratory Universe by CLIA Complexity The most significant trend in molecular laboratories during 2012 was the adoption of moderately complex tests by laboratories that had not performed molecular diagnostics in the past. Molecular Laboratories By Testing Menu Total = 2,006 Total = 1,830-3% Highly Complex, with LDT +2% Highly Complex, no LDT Moderately Complex +39% The reduction in labs performing LDTs is attributable to the availability of more FDA-cleared assays such as the Roche TaqMan CMV and the BioFire Respiratory Panel The growth in moderately complex laboratories is the result of the adoption of Meridian and Cepheid assays. Although the BioFire panel is moderately complex it was adopted by labs that already performed one or more molecular assays 4 Market Diagnostics International
5 Q1 2014: A Solid Start to the Year GeneXpert System Placements +78% Commercial Placements +45% Clinical Revenue +26%, Commercial Clinical +19% Commercial Clinical Xpert Test Revenue +24%* International Commercial Clinical Revenue +47% Continued Menu Execution Xpert HPV, Xpert Norovirus CE-IVD Release in Early April 5 Cepheid * Normalized for Q113 Backorder-Related Revenue
6 Strategic Drivers GLOBAL MARKET EXPANSION APPLICABLE MARKET EXPANSION MAINTAINING GROWTH LEADERSHIP BROAD MENU EXPANSION 6 Cepheid
7 Broad Menu Expansion 2 Systems Expansion 1 Test Expansion 3 Remote Connectivity and Data Management 7 Cepheid
8 Development of Disease Portfolio Other Genetic Disease Oncology Infectious Disease Bacterial Viral Cervical Breast Bladder Prostate Lung 8 Cepheid
9 Develop The Most Compelling Test Menu Offering. Available Now MRSA Surveillance SA Nasal Complete C. diff & C. diff/epi vana for VRE MRSA/SA SSTI MRSA/SA Blood Culture EV Flu MTB/RIF CT/NG GBS & GBS Lim Broth Factor II&V 19 Norovirus Carba-R MRSA Surveillance-Next Gen Flu/RSV CW Flu/RSV Trichomonas 33 SA Nasal Complete-Next Gen Pertussis Gastro Panel HSV 1/2 Typing Vaginitis CW Vaginitis CW CT/NG BCR-ABL Ultra Breast CA Stratifier Bladder CA Monitor Bladder CA Symptomatic HPV (Cervical CA) HIV Quant HCV Quant HBV Quant 39 Group A/C Strep Meningitis/Encephalitis GBS Ultra CW GBS Ultra CW Group A/C Strep CW HPV (Cervical CA) Breast CA Signature 16 MRSA Surveillance SA Nasal Complete C. diff/epi vana/vanb for VRE MRSA/SA SSTI MRSA/SA Blood Culture Norovirus (NEW!) EV Flu MTB/RIF CT & CT/NG GBS Factor II&V HPV (Cervical CA) (NEW!) BCR-ABL Monitor 24 Carba-R Trichomonas MRSA Surveillance-Next Gen Flu/RSV Bladder CA Monitor/Sympt BCR-ABL Ultra HIV Quant HIV Qualitative HCV Quant 33 SA Nasal Complete-Next Gen Group A/C Strep Meningitis/Encephalitis Pertussis Gastro Panel HSV 1/2 Typing Vaginitis GBS Ultra HBV Quant Breast CA Stratifier Breast CA Signature 36 Pancreatic CA Monitor EBV / NPC Screen EBV / NPC Monitor = US = International 9 Cepheid Notes: Targeted Test Menu Subject to Revision; CW = CLIA-Waived in Italics Represent Product Improvements and are Excluded from Total Test Counts
10 Develop The Most Compelling Test Menu Offering. Available Now MRSA Surveillance SA Nasal Complete C. diff & C. diff/epi vana for VRE MRSA/SA SSTI MRSA/SA Blood Culture EV Flu MTB/RIF CT/NG GBS & GBS Lim Broth Factor II&V Norovirus Carba-R Norovirus 19 MRSA Carba-R Surveillance-Next Gen Flu/RSV MRSA Surveillance-Next Gen CW Flu/RSV Trichomonas CW Flu/RSV Trichomonas SA Nasal Complete-Next Gen Pertussis Gastro Panel HSV 1/2 Typing Vaginitis CW Vaginitis CW CT/NG BCR-ABL Ultra Breast CA Stratifier Bladder CA Monitor Bladder CA Symptomatic HPV (Cervical CA) HIV Quant HCV Quant HBV Quant 39 Group A/C Strep Meningitis/Encephalitis GBS Ultra CW GBS Ultra CW Group A/C Strep CW HPV (Cervical CA) Breast CA Signature 16 MRSA Surveillance SA Nasal Complete C. diff/epi vana/vanb for VRE MRSA/SA SSTI MRSA/SA Blood Culture Norovirus (NEW!) EV Flu MTB/RIF CT & CT/NG GBS Factor II&V HPV (Cervical CA) (NEW!) BCR-ABL Monitor Carba-R 33 Trichomonas MRSA Carba-R Surveillance-Next Gen Flu/RSV Trichomonas Bladder MRSA CA Surveillance-Next Monitor/Sympt Gen BCR-ABL Flu/RSV Ultra HIV Bladder Quant CA Monitor/Sympt HIV Qualitative BCR-ABL Ultra HCV Quant HIV Quant HIV Qualitative HCV Quant SA Nasal Complete-Next Gen Group A/C Strep Meningitis/Encephalitis Pertussis Gastro Panel HSV 1/2 Typing Vaginitis GBS Ultra HBV Quant Breast CA Stratifier Breast CA Signature 36 Pancreatic CA Monitor EBV / NPC Screen EBV / NPC Monitor = US = International 10 Cepheid Notes: Targeted Test Menu Subject to Revision; CW = CLIA-Waived in Italics Represent Product Improvements and are Excluded from Total Test Counts
11 GeneXpert System Enables Broad Range of Oncology Opportunities Measure many targets simultaneously ANY other validated RNA expression signature Breast CA Recurrence Signature BCR-ABL Monitor (CML) Sensitively detect translocations in blood Oncology Product Development Using qpcr Decentralized Path using FFPE tissue specimens Breast CA Classifier Prostate CA Recurrence Signature 11 Cepheid Bladder CA Screen At-Risk Bladder CA Symptomatic Bladder CA Monitor Quantitate RNA targets in urine KRAS Pancreatic CA Monitor Quantitate mutations in ctdna Others EGFR, ALK, KRAS Lung CA Monitor
12 Establishing A Full Global Market Presence Direct Distributed Direct & Emerging Markets Distributed & Emerging Markets 12 Cepheid Emerging Markets
13 Expanding Scope of Applicable Markets GX-1 Infinity 80 GX-2 Hospitals Infinity 48s GX-4 GX Cepheid
14 Expanding Scope of Applicable Markets Infinity 80 Infinity 48s Independent Labs 14 Cepheid
15 Industry Leading Throughput and Operating Efficiency 2:1 3:1 4:1 4:1 4:1 Advantage Advantage Advantage Advantage Advantage Infinity-80 Gen Probe Tigris Gen Probe Panther BD Viper Roche Cobas Taqman 96 Abbott m2000 CT/NG Testing Over One 8-Hour shift 15 Cepheid
16 Menu Application on High Throughput Systems Manufacturer Test Menu On Line Test Capability Cepheid Roche (6800, 8800)* Hologic (Tigris) Qiagen (QiaSymphony RCU) Becton Dickinson (Viper) Abbott (m2000) US:14 EU:17 US: 9 EU:17 US: 6 EU: 6 US: 2 EU: 2 US: 4 EU: 4 US: 8 EU:14 Unlimited Cepheid * Roche 6600/8800 not yet released.
17 Expanding Scope of Applicable Markets GX-1 GX-2 Alternate Sites POL s Urgent Care Nursing Homes Retail Outlets Cruise Ships Home GX-4 17 Cepheid
18 We are a better way. 18 Cepheid Cepheid NASDAQ: CPHD Questions? Contact Investor Relations: investor.relations@cepheid.com or tel. (408)
Investing in Innovation. John Bishop CEO & Chairman Baird Healthcare Conference 4 September, 2014
Investing in Innovation John Bishop CEO & Chairman Baird Healthcare Conference 4 September, 2014 1 Cepheid Cepheid Forward-Looking Statement During the course of this presentation, we may make projections
More informationWe Innovate for Life John Bishop Chairman and Chief Executive Officer June 2016
We Innovate for Life John Bishop Chairman and Chief Executive Officer June 2016 1 Cepheid Forward-Looking Statement During the course of this presentation, we may make projections or other forward-looking
More informationCepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012
Cepheid The MDx Growth Leader William Blair Growth Stock Conference June 12, 2012 Forward Looking Statement During the course of this presentation, we may make projections or other forward looking statements
More informationCepheid: Delivering a Better Way
Cepheid: Delivering a Better Way Dieneke Brockmans March 14, 2017 1 Cepheid Our Mission Delivering a better way to improve patient outcomes by enabling access to molecular diagnostic testing everywhere.
More informationUnified Xpert MTB/RIF Forecasting Initiative
Photo: Riccardo Venturi Unified Xpert MTB/RIF Forecasting Initiative Wayne van Gemert WHO Global TB Programme, Geneva WHO ANNUAL MEETING WITH HIV DIAGNOSTIC MANUFACTURERS AND STAKEHOLDERS 11 March 2016
More information2017 & Beyond Next Phase Innovative Growth Drivers. Analyst Event July 27, 2015
2017 & Beyond Next Phase Innovative Growth Drivers Analyst Event July 27, 2015 1 Forward-Looking Statement During the course of this presentation, we may make projections or other forward-looking statements
More informationCepheid Update POC QA. Gwynn Stevens, PhD Director Virology Programme HBDC
Cepheid Update POC QA Gwynn Stevens, PhD Director Virology Programme HBDC What will be covered? Quick intro to Cepheid Identification of the need Recognition of the challenges Technology as part of the
More informationInfectious Disease Diagnostics
Infectious Disease Diagnostics Tackling Infectious Diseases Uppsala Health Summit - October10 th, 2017 Stephan Jäger, Roche Diagnostics GmbH When to tackle infectious diseases Prevention & action contribution
More informationCommercial Assays an Overview. Molecular Workshop
Commercial Assays an Overview Molecular Workshop Commercial Assays By Discipline Infectious Disease Blood borne viruses Respiratory Viruses and Bacteria Enteropathogens STD s bacteria, viruses and parasites,
More informationInnovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays
About the author Disclaimer EXECUTIVE SUMMARY Molecular diagnostic technologies Healthcare-associated infections Sexually transmitted HPVs HIV and hepatitis viruses Market outlook and forecasts Molecular
More informationGeneXpert System. On-Demand Molecular Testing for the Physician Office Laboratory
On-Demand Molecular Testing for the Physician Office Laboratory GeneXpert System How can on-site testing positively impact patient care and clinic operations? A better way. On-site molecular diagnostics
More informationSchedule of Accreditation
Schedule of Accreditation Organisation Name National Virus Reference Laboratory INAB Reg No 326MT Contact Name Eimear Malone Address University College Dublin, Belfield, Dublin Contact Phone No 01-7161319
More informationDisruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
More informationAMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS
AMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS Take Control, Molecular Control. 02 04 05 06 06 07 08 08 AMPLIRUN TOTAL RESPIRATORY INFECTIONS TUBERCULOSIS INFECTIONS GASTROINTESTINAL
More informationSegment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage
Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Royal Liverpool & Broadgreen University Hospitals NHS Trust Department of Virology Liverpool Clinical Laboratories Royal Liverpool and Broadgreen
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationAnti-Infective Clinical Trials
Anti-Infective Clinical Trials The extensive clinical training and experience of our infectious disease staff places us in a unique position to fully appreciate the requirements of our clients conducting
More informationSEXUAL HEALTH LAB PRODUCTS
SEXUAL HEALTH LAB PRODUCTS Quick, reliable results for in-office testing Start treatments sooner. Enhance patient outcomes. Long waits for results. Delayed diagnosis and treatment. Cancelled follow-up
More informationMolecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research
Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research " Projected to grow at a CAGR of almost 9% from 2016 to 2024, the molecular diagnostics market
More information8/18/2011. How Far We ve Come. Update on Laboratory Diagnosis of Viral Infections. Rapid Viral Diagnostic Techniques. Goals of Testing for Viruses
How Far We ve Come Update on Laboratory Diagnosis of Viral Infections Jim Dunn, Ph.D., D(ABMM) Cook Children s Medical Center Ft. Worth, TX 1948 cell culture techniques standardized 1956 immunofluorescent
More informationQiagen NV (QIA) - Product Pipeline Analysis, 2017 Update
Qiagen NV (QIA) - Product Pipeline Analysis, 2017 Update Qiagen NV (QIA) - Product Pipeline Analysis, 2017 Update Sector Publishing Intelligence Limited (SPi) has been marketing business and market research
More informationOverview of HIV Testing Practices and Technology
Overview of HIV Testing Practices and Technology 2019 HIV Diagnostics Conference March 25 th, 2019 Michele Owen, Ph.D National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease
More informationNASDAQ: CPHD. Defining on-demand molecular diagnostics
NASDAQ: CPHD Defining on-demand molecular diagnostics Forward Looking Statement During the course of this presentation, we may make projections or other forward looking statements regarding future events
More informationMolecular Testing in Infectious Diseases. Objectives 5/9/2014. Implementing Molecular Testing for Infectious Diseases Diagnosis
Molecular Testing in Infectious Diseases Elizabeth Palavecino, M.D. Director Clinical Microbiology Co-Director Clinical & Translational Mass Spec Center Associate Professor of Pathology Wake Forest School
More informationDiagnostics HPV Testing
22 SOURCES COMPANIES: HOLX, QGEN, RHHBY, ROG VX BDX HOLX S HPV TESTING BUSINESS QGEN S HPV TESTING BUSINESS Roche Leads in HPV Platform Switches Roche s cobas continues to capture the majority of HPV platform
More informationPOSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH
POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH Akos Somoskövi, M.D., Ph.D. and Giorgio Roscigno, M.D. ANNUAL GLI MEETING, 4 th OCTOBER 2010 MERIEUX FOUNDATION, ANNECY Integrated Laboratory Network
More information9/23/2014. Wisconsin Association of Physician Assistants October 10, 2014
Personalized (Precision) Medicine Wisconsin Association of Physician Assistants October 10, 2014 Disclosures I am an employed by Promega Corporation, a Madison based international biotechnology company
More informationPoint of Care Tests for respiratory viruses: impact on clinical outcomes of patients
Point of Care Tests for respiratory viruses: impact on clinical outcomes of patients Dr Sacha Stelzer-Braid Postdoctoral Scientist Virology Research Laboratory (VRL), UNSW and POWH @DrSachaSB Outline 1.
More informationGlobal Hepatitis B and C Diagnostics Market
Global Hepatitis B and C Diagnostics Market 2016-2020 Global Hepatitis B and C Diagnostics Market 2016-2020 BioPortfolio has been marketing business and market research reports from selected publishers
More informationQIAGEN Research & Development. Pipeline 2009/2010
QIAGEN Research & Development Pipeline 2009/2010 QIAGEN Analyst and Investor Day 2010 Dr. Joachim Schorr Senior Vice President Global Research & Development New York, February 11th, 2010 Agenda R&D @ QIAGEN
More informationNew Molecular Diagnostic Assays for Solana Performance Assessment, Workflow Analysis, and Clinical Utility
New Molecular Diagnostic Assays for Solana Performance Assessment, Workflow Analysis, and Clinical Utility Gerald A. Capraro, Ph.D., D(ABMM) Director, Clinical Microbiology Carolinas Pathology Group Atrium
More informationQIAGEN. Sample & Assay Technologies. New Approaches in Biomarker Detection. SEAP/SEC/SEPAF Zaragoza May 2011
QIAGEN New Approaches in Biomarker Detection SEAP/SEC/SEPAF Zaragoza May 2011 Dr. Stephen Little Vice President Personalized Healthcare - 1 - DxS is a Personalised Medicine Company that meets the needs
More informationBACTERIOLOGY PROFICIENCY TESTING PROGRAM
BACTERIOLOGY PROFICIENCY TESTING PROGRAM Comprehensive Category September 6, 2016 If you have any questions or comments, please contact either: Dr. Wendy Archinal Nellie Dumas Dr. Kimberlee Musser Phone:
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationCommunity-Based Point-of-Care Testing: From Innovative Care Model to Common Practice
Community-Based Point-of-Care Testing: From Innovative Care Model to Common Practice Donald G. Klepser, PhD, MBA Associate Professor University of Nebraska Medical Center Brian Bobby Rite Aid Vice President,
More informationAdvaMedDx Value Assessment Framework in Practice
AdvaMedDx Value Assessment Framework in Practice Application of the Comprehensive Assessment of the Value of Diagnostic Technologies Framework to Abbott s 4th Generation ARCHITECT HIV Antigen/Antibody
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationSee how you can guide the path her cancer takes
See how you can guide the path her cancer takes 1 Idylla : easy, rapid and accurate molecular medicine for every patient Paola Valente Strategic Marketing Biocartis 6th meeting on external quality assessment
More informationJ.P. Morgan Global Healthcare Conference
J.P. Morgan Global Healthcare Conference Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in
More informationMenu and flexibility with the QIAscreen HPV PCR Test
Menu and flexibility with the QIAscreen HPV PCR Test Sample to Insight HPV and Cervical cancer Worldwide, HPV is one of the most common STIs Persistent infection with high-risk HPV types is linked to virtually
More informationSimpler QC for your Quality Systems. Thermo Scientific AcroMetrix Molecular Standards and Quality Controls. North American version
Simpler QC for your Quality Systems Thermo Scientific AcroMetrix Molecular Standards and Quality Controls North American version AcroMetrix Contents Introduction 4 Superior QC: AcroMetrix molecular quality
More informationgeneombio Technologies
MOLECULAR DIAGNOSTICS SERVICES geneombio Technologies SN Test Method Test code Type of Sample Type of container TAT* Frequency MRP Infectious diseases - detection, quantification, genotyping assays A MTB
More informationOpportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental
More informationNew Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention
New Generation of Nucleic Acid Testing Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Percentage (%) Persons Living with Diagnosed or Undiagnosed HIV Infection
More informationOraSure Technologies. JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014
OraSure Technologies JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014 Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including
More informationNAT / BLOOD SCREENING - PRODUCT RANGE
NAT / BLOOD SCREENING - PRODUCT RANGE QC Sample Name Analytes Assay / Instrument Page QConnect TriScreen Roche cobas TaqScreen MPX Test, v 2.0 (s201) Roche cobas MPX Test (6800/8800) QConnect Grifols Ultrio
More informationEconomic Value Lab Efficiencies Safety Clinical Outcomes. Visit BD Booth AACC/ASCLS 2009 Annual Meeting
Economic Value Lab Efficiencies Safety Clinical Outcomes Visit BD Booth 1225 AACC/ASCLS 2009 Annual Meeting BD Events & Co-Promotions Join us this year at booth #1225 to discover the full spectrum of solutions
More informationPractical Aspects of Standardisation for a Global Controls Manufacturer
Practical Aspects of Standardisation for a Global Controls Manufacturer MRSA SoGAT Clinical Diagnostic Meeting NIBSC, UK June 25, 2008 Frank Opdam PhD, AcroMetrix Standardisation A fundamental goal of
More informationBACTERIOLOGY PROFICIENCY TESTING PROGRAM
BACTERIOLOGY PROFICIENCY TESTING PROGRAM Comprehensive Category January 19, 2016 If you have any questions or comments, please contact either: Dr. Wendy Archinal Nellie Dumas Dr. Kimberlee Musser Phone:
More informationMultiplex Syndromic Testing s Effect on Public Health Molecular Testing & Emerging Technology WCLN Workshop April 28, 2016
Multiplex Syndromic Testing s Effect on Public Health Molecular Testing & Emerging Technology- 2016 WCLN Workshop April 28, 2016 Objectives Learn what current multi-target testing activities are ongoing
More informationSTOCS-H Scottish TOC Study HPV test comparison
STOCS-H Scottish TOC Study HPV test comparison What is entailed? Trial of new HPV tests on residual sample after HC2 result obtained, reported and acted on Complements English Sentinel Sites HPV Multi-test
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationIn Situ Hybridization: Market Strategies and Forecasts, US,
In Situ Hybridization: Market Strategies and Forecasts, US, 2018-2024 Table of Contents In Situ Hybridization: Executive Summary The study is designed to give a comprehensive overview of the In Situ Hybridization
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationEVALUATION OF THE COBAS LIAT (ROCHE ) AND THE LIAISON MDX (DIASORIN )
EVALUATION OF THE COBAS LIAT (ROCHE ) AND THE LIAISON MDX (DIASORIN ) Delefortrie Quentin Intern in Clinical Pathology Corata, 20-21 September 2018 Presentation Plan Evaluation of the cobas Liat Influenza
More informationGLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationPanther has new prey
Raising the Bar for Performance Testing Panther has new prey The Aptima HIV-1 Quant Dx assay leads the hunt for HIV-1 diagnosis and viral load monitoring. Freedom to work the way you choose Run what assays
More informationUpdate on WHO Prequalification of IVDs
Update on WHO Prequalification of IVDs Geneva, 11 March 2016 Mercedes Perez Gonzalez Anita Sands Prequalification Team - Diagnostics World Health Organization Outline Progress and Pipeline Ongoing concerns
More informationCollection Container Category Source Tests Order Codes
Nasal Nares culture for MRSA screen ONLY (Outpatient) NSL Room BD BBL Dual Culture Swab (Red Cap) Ear Ear culture EARC Room Eye Eye Culture EYEC Room Cultures Vaginal Genital Culture GEN or GC Room Superficial
More informationfor Microbiology Quality Assessment Programmes for HPV and MRSA Effect of change to assessment categories for HBV DNA Dr Vivienne James SoGAT 2009
for Microbiology Quality Assessment Programmes for HPV and MRSA Effect of change to assessment categories for HBV DNA Dr Vivienne James Overview Update on the HPV scheme introduced in 2009 MRSA screening
More informationM E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 7 Microbiology 2017 MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Evaluation Criteria... 2 Microbiology
More informationLukas Bubendorf Pathologie. Liquid biopsies
Lukas Bubendorf Pathologie Liquid biopsies Liquid biopsies 1. Circulating cell-free tumor-dna (ctdna) 2. Circulating tumor cells (CTC) Source: Sysmex CTCs ctdna ctrna exosomes Quantification Protein RNA
More informationAccuSet HBV Worldwide Performance Panel
PACKAGE INSERT 0805-033 INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HBV test methods. Characterized samples
More informationREGULATIONS FOR THE POSTGRADUATE DIPLOMA IN MOLECULAR AND DIAGNOSTIC PATHOLOGY (PDipMDPath)
REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN MOLECULAR AND DIAGNOSTIC PATHOLOGY (PDipMDPath) (See also General Regulations and Regulations for Taught Postgraduate Curricula) M.129 Admission requirements
More informationRoche at a Glance An Introduction to our Company. February 2013
Roche at a Glance An Introduction to our Company February 2013 Basic facts at a glance Founded 1896 in Basel, Switzerland Founding families still hold majority stake Employing 80,000 people Currently active
More informationSiemens Healthcare Diagnostics
Siemens Healthcare Diagnostics A Global Industry Leader 3.7bn in sales More than 14,500 employees Serving 30,000 customers in more than 120 countries Approximately 244,000 instruments installed R&D spending
More informationThe Application of molecular POCT for Influenza and Group A Strep Detection
The Application of molecular POCT for Influenza and Group A Strep Detection Gregory J. Berry, Ph.D., D(ABMM) Assistant Professor, Pathology and Laboratory Medicine Zucker School of Medicine at Hofstra/Northwell
More informationNAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL
NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL Susan Novak-Weekley, S(M), ASCP, Ph.D., D(ABMM) Director of Microbiology,
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationUCL-Advanced Diagnostics. 2015/16 Service Update
UCL-Advanced Diagnostics 2015/16 Service Update About UCL-Advanced Diagnostics UCL Advanced Diagnostics (UCL-AD) is the immunohistochemistry, in situ and molecular diagnostics service arm of the UCL-Cancer
More informationESCMID Online Lecture Library. by author
. Diagnostic molecular microbiology: first and next 25 years Mario Poljak Institute of Microbiology and Immunology Faculty of Medicine, University of Ljubljana, Slovenia Molecular methods methods based
More informationPoint-of-Care Molecular Testing
Point-of-Care Molecular Testing Waived Testing April 28, 2016 Raymond P. Podzorski, Ph.D., D(ABMM) Ph.D. Microbiologist St. Mary s Hospital Laboratory Wisconsin Region SSMHC Madison, WI 608-258-6393 raymond_podzorski@ssmhc.com
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationMicrobiology EQA Product Portfolio
Labquality EQAS Microbiology EQA Product Portfolio Clinically relevant external quality assessment program for microbiology Bacterial serology Bacteriology Mycology Parasitology Preanalytics Virology Labquality
More informationREFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - Executive Summary Human PapillomaVirus (HPV) Vaccine Sales Expected to Grow Modestly During the Forecast
More informationHIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26
1 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Viral Load Quality Assessment Program Summary
More informationHuman Papillomaviruses: Biology and Laboratory Testing
For our patients and our population Human Papillomaviruses: Biology and Laboratory Testing Geoffrey Higgins Microbiology and Infectious Diseases For our patients and our population HPV Associated Cancers
More informationDiagnostics Division. Daniel O Day COO Roche Diagnostics
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationBeckman Coulter introduces Sentinel Pancreatic Amylase reagent and calibrator on AU Clinical Chemistry Analyzers
PREVIOUSLY RELEASED BREA, CALIF. (June 23, 2016) Beckman Coulter Diagnostics is pleased to announce the release of a new pancreas specific amylase assay. The Sentinel Pancreatic Amylase reagent and calibrator
More informationThe New Regulations - Special IVD Issues
The New Regulations - Special IVD Issues Dirk Stynen, Ph. D. President - Principal Consultant Qarad Geel, Belgium RMD Brussels October 2018 The IVD Regulation 2017/746 October 29, 2018 www.qarad.com 2
More informationAbout HPV. Human papillomavirus (HPV) is a group of viruses that are extremely common worldwide. Theree are more than 100 types of HPV, of which at
Cervical Cancer & HPV What is HPV Human papillomavirus (HPV) is a group of viruses that are extremely common worldwide. About HPV Theree are more than 100 types of HPV, of which at least 13 are cancer-causing
More informationXpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
More informationAccelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
More informationRoche Diagnostics. Daniel O Day COO Roche Diagnostics. Vontobel Summer Conference June 22, 2012
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationCommitted to innovation and growth
Committed to innovation and growth Roland Diggelmann, CEO Roche Diagnostics Paris, November 30, 2016 Q3 2016 Group results Diagnostics Business model & strategy Q3 2016 overview Investing in innovation
More informationIndustry Sponsored Symposia. Québec City, CANADA JULY 10 TO 13,
19th biennial conference of the International Society for sexually transmitted diseases Research Québec City, CANADA JULY 10 TO 13, 2011 Industry Sponsored Symposia www.isstdrquebec2011.com SUNDAY JULY
More informationDIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC)
DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC) R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p
More informationEvaluation of the new Abbott mplus feature: Impact on clinical laboratory efficiencies with Abbott RealTime HIV-1, HCV, HBV and CT/NG assays
JCM Accepts, published online ahead of print on 2 October 2013 J. Clin. Microbiol. doi:10.1128/jcm.01672-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 Evaluation
More informationImage of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS MAY 2017 1 Infectious viral pathogens are a significant global health threat to mankind 2 Since the approval
More informationResults of the College of American Pathologists (CAP) Proficiency Program for CMV, EBV, and BKV Viral Load Testing
2009 College of American Pathologists. The College does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The College hereby authorizes
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Microbiology Department North Tyneside General Hospital Rake Lane North Shields NE29 8NH Contact: Karen Morris Tel: +44 (0)3448118111 ext
More informationMENU PRODUCT MOLECULAR. International Product Listing. Simplexa Molecular Kits Integrated Cycler Molecular Reagents and Primer Pairs
International Product Listing MOLECULAR PRODUCT MENU Simplexa Molecular Kits Integrated Cycler Molecular Reagents and Primer Pairs Products are not intended for donor screening. Simplexa Molecular Kits
More informationNext Generation Rapid Diagnostics
Next Generation Rapid Diagnostics INTERNATIONAL PRODUCT CATALOG Quidel is a leading manufacturer of diagnostic healthcare solutions serving to enhance the health and well-being of people around the globe
More informationThe Role of POCT in Management of Infectious Disease in the Critical Care Setting
The Role of POCT in Management of Infectious Disease in the Critical Care Setting Nathan A Ledeboer Associate Professor of Pathology Medical College of Wisconsin Medical Director, Microbiology and Molecular
More informationGrant Summary Report: Expansion of Nucleic Acid Amplification Testing for TB In Public Health Laboratories
Grant Summary Report: Expansion of Nucleic Acid Amplification Testing for TB In Public Health Laboratories Angela M. Starks, Ph.D. Team Lead, Laboratory Capacity Team Laboratory Branch June 11, 2012 National
More informationFifteen years of molecular EQA: progress and challenges
Fifteen years of molecular EQA: progress and challenges Anton M van Loon 1, Stuart West 2 and Paul Wallace 2 1 Department of Virology, UMC Utrecht, The Netherlands 2 QCMD, Glasgow, Scotland Key Issues
More informationView Report Details. Global Coronary Stent Market
View Report Details Global Coronary Stent Market ------------------------------------------------- 2013 View Report Details Executive Summary Coronary heart diseases are nowadays becoming more and more
More information